tbuckley/cabot-search huggingface dataset:
Carbamazepine and Fatal Eosinophilic Myocarditis
Authors: Mark B. Salzman, Elsa Valderrama, Sunil K. Sood
Journal: New England Journal of Medicine (1997)

To the Editor: We describe a 13-year-old boy with attention deficit–hyperactivity disorder in whom fever, rash, conjunctivitis, hepatitis, myocarditis, and eosinophilia developed and who died about two months after the start of carbamazepine therapy. The cardiopulmonary resuscitation (CPR) of this patient was reported in an article on transvenous right ventricular pacing during CPR in children with acute cardiomyopathy.1 The child was an inpatient on a psychiatric unit. His carbamazepine treatment (100 mg twice a day) was initiated for aggressive and impulsive behavior after he did not respond to methylphenidate and clonidine. The carbamaz-epine dose was gradually increased to 800 mg . . .
Effect of One-HLA-DR-Antigen–Matched and Completely HLA-DR–Mismatched Blood Transfusions on Survival of Heart and Kidney Allografts
Authors: Emma L. Lagaaij, I. Philip H. Hennemann, Marieke Ruigrok, Michiel W. de Haan, Guido G. Persijn, Annemarie Termijtelen, Godefridus F.J. Hendriks, Willem Weimar, Frans H.J. Claas, Jon J. van Rood
Journal: New England Journal of Medicine (1989)

Blood transfusions can influence the survival of organ allografts favorably, in spite of the danger of sensitization. We investigated the influence of HLA compatibility between blood donors and transfusion recipients on the production of HLA antibodies and on graft survival. Among recipients of transfusions who shared one HLA-DR antigen with their respective donors, antibodies developed in 6 of 28 who had received one transfusion, in 2 of 16 who had received three transfusions, and in 4 of 24 who had undergone renal transplantation. Among recipients who were mismatched with their donors for both HLA-DR antigens, the rate of sensitization was significantly higher in all three of these groups (18 of 30, P = 0.02; 12 of 16, P = 0.0007; and 12 of 22, P = 0.001). The survival of kidney allografts among graft recipients who were given transfusions and shared one HLA-DR antigen with their blood donors (81 percent at five years) was significantly higher than among recipients who were given transfusions and were mismatched for both HLA-DR antigens (57 percent; P = 0.02) or among recipients who were not given transfusions (45 percent; P = 0.001). There was no difference in graft survival between patients who received transfusions mismatched for two HLA-DR antigens and those who were not given transfusions. We conclude that allograft survival can be improved by pretransplantation blood transfusion when the transfusion recipients share at least one HLA-DR antigen with their donors. In view of the increased rate of sensitization and the lack of improvement in graft survival, the transfusion of blood mismatched for two HLA-DR antigens appears to be contraindicated in candidates for transplantation. (N Engl J Med 1989;321:701–5.)
Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.
Authors: N. P. Shah, J. E. Cortes, C. A. Schiffer, P. le Coutre, E. Bahceci, A. Lambert, G. Saglio
Journal: Journal of Clinical Oncology (2010)

6512 Background: Dasatinib, a potent tyrosine kinase inhibitor, is indicated for treating imatinib-resistant or -intolerant patients with CML (all phases) or Ph+ acute lymphoblastic leukemia. Based upon results of a phase III dose-optimization study (CA180-034), the approved dosing regimen for patients with CP-CML with resistance, intolerance, or suboptimal response to imatinib was changed to 100 mg once daily from the initially approved 70 mg twice daily. This study assesses the efficacy and safety of dasatinib 100 mg once daily with a minimum follow-up of 48 months. Methods: Study design and endpoints have been described previously. Patients were randomized using a 2x2 factorial design to 1 of 4 treatment arms: 100 mg once daily (n=167), 50 mg twice daily (n=168), 140 mg once daily (n=167), and 70 mg twice daily (n=168). Results: Similar response rates were achieved in all arms and similar rates of progression-free survival (PFS; defined as no loss of complete hematologic response or major cytogenetic response, development of advanced disease, elevated white blood cells, or death as recorded by site investigators) were observed in resistant patients with or without baseline BCR-ABL mutations. At the 36-month follow-up, the PFS rate with 100 mg once daily was highest (Table). PFS data from a minimum follow-up of 48 months will be presented. The long-term safety profile of dasatinib 100 mg once daily will also be described. The likelihood of eventually achieving long-term endpoints based on cytogenetic status at 6 and 12 months will be determined. Conclusions: With a minimum follow-up of 48 months, dasatinib 100 mg once daily offers an acceptable benefit-risk profile for patients with CP-CML who are resistant, intolerant, or suboptimally responsive to imatinib. The landmark analyses and the long-term data to be shown will provide useful outcome information to clinicians treating patients with dasatinib according to achieved responses at key intervals, particularly among those with an allogeneic stem cell transplantation option. 100 mg once daily 70 mg twice daily 140 mg once daily 50 mg twice daily 24-month CCyR (last assessment) 50% 53% 50% 49% 36-month PFS 73% 67% 60% 72% 36-month OS 87% 80% 84% 84% Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb Bristol-Myers Squibb, Chemgenix, Merck, Novartis, Wyeth Bristol-Myers Squibb, Novartis Bristol-Myers Squibb, Merck, MSD, Novartis Bristol-Myers Squibb, Novartis
Analysis of 51 Patients with Horseshoe Kidney
Authors: James F. Glenn
Journal: New England Journal of Medicine (1959)

HORSESHOE kidney is considered to be one of the more common congenital urologic anomalies, probably occurring in about 0.25 per cent of the general population.1 It is estimated that over 1000 cases are recorded in the literature, either included in various series or as single case reports.2 It has been stated that the existence of horseshoe kidney strongly predisposes to serious renal disease,3 and the vast majority of articles in the literature suggest that the condition is not only prevalent but also of serious consequence.4 The literature deals mainly with the surgery of the horseshoe kidney and with the various . . .
40P A survey on smoking and tobacco control perceptions from physicians and employees working in an Italian cancer center
Authors: D. Galetta, A. Catino, M.E. De Palma, A. Acito, R. Lacalamita, M. Longo, S. De Summa, A. Di Lauro, F. D'Ecclesiis, F. Giotta
Journal: Journal of Thoracic Oncology (2016)
Virostatic Therapy for Advanced Lymphoproliferation Associated with the Epstein–Barr Virus in an HIV-Infected Patient
Authors: Wolfgang Schmidt, Ioannis Anagnostopoulos, Hans Scherübl
Journal: New England Journal of Medicine (2000)

Transmyocardial Laser RevascularizationTo the Editor: The placebo effect of surgery for the treatment of angina that is mentioned by Lange and Hillis (Sept.30 issue) 1 in their editorial on transmyocardial laser revascularization deserves elaboration.In the era before direct coronary revascularization, internal-thoracic-artery ligation was touted as a method to increase myocardial blood flow and relieve anginal symptoms.Initial reports by Ellis et al. 2 and Kitchell et al. 3 indicated that 68 to 75 percent of patients had clinical improvement, including approximately 35 percent who had complete relief and 42 percent with objective improvements, as measured electrocardiographically.These investigators were honest and intelligent but not impartial observers.Double-blind studies conducted later by Cobb et al. 4 and Dimond et al. 5 demonstrated that a sham thoracotomy alone could decrease the need for nitroglycerin and increase exercise tolerance and that it produced subjective improvement in more than 35 percent of patients.These results are similar to the improvement among 34 percent of the patients in the British study of transmyocardial laser revascularization mentioned by Lange and Hillis.When perfusion scans do not correlate in time or magnitude with the patient's clinical improvement, the more subjective data on improvement of symptoms must be approached with great skepticism.As was the case in earlier studies, the thoracotomy incision alone may have an important effect directly or indirectly on the patient's perception of pain.The fact that a patient has already undergone the surgical procedure of last resort has a high likelihood of affecting a physician's choice of treatment plans, and thus study outcome.It may be completely correct that transmyocardial laser revascularization benefits patients with chronic angina.However, given the substantial morbidity and mortality (9 to 15 percent mortality among the patients who were crossed over to transmyocardial laser revascularization in the studies by Frazier et al. 6 and Allen et al. 7 discussed by Lange and Hillis), the potential for a placebo effect must always be remembered.
Long-Term Results of Treatment of Thyrotoxicosis in Children and Adolescents with Radioactive Iodine
Authors: Alberto Hayek, Earle M. Chapman, John D. Crawford
Journal: New England Journal of Medicine (1970)

From 1941 through 1968 30 patients between the ages of eight and 18 years were treated with radioiodine for thyrotoxicosis. Two patients received 130I, and 28 131I. There were two males and 28 females. The dose of 131I ranged from 2 to a maximal cumulative dose of 32 mCi in two separate doses with an average dose of 6.6 mCi per patient. The mean length of follow-up observation was 9.2 years. Prompt remission of the disease was obtained with a single dose in 25 cases. Permanent hypothyroidism developed in eight patients (26 per cent). Recurrence of thyrotoxicosis associated with benign nodular hyperplasia was observed in only one case 17 years after treatment with 130I. Twelve of the females treated with 131I have given birth to 18 healthy children. One female treated with 130I has an abnormal reproductive history. No deaths and no evidence of cancer or leukemia were seen.
Efficacy of the Priority Review Voucher Program
Authors: Ameet Sarpatwari, Aaron S. Kesselheim
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Azygography in the Evaluation of Operability of Pulmonary Carcinoma
Authors: David B. Skinner, Jack R. Dreyfuss, George L. Nardi
Journal: New England Journal of Medicine (1962)

COSTAL intraosseous venography (azygography) is the only technic currently available that permits roentgenologic visualization of the thoracic venous drainage. This procedure, though well defined,1 has not been widely utilized in the preoperative evaluation of the patient with pulmonary carcinoma. Fry et al.2 and Lessmann, Schobinger and Lasser3 have suggested the value of this technic in demonstrating mediastinal invasion by pulmonary neoplasms. We are reporting our experience with the method in the clinical evaluation of 46 patients with bronchogenic carcinoma. It has proved of value in defining operability.Materials and MethodsForty-six patients with an admission diagnosis of carcinoma of the . . .
Initial Chemotherapeutic Doses and Survival in Patients with Limited Small-Cell Lung Cancer
Authors: Rodrigo Arriagada, Thierry Le Chevalier, Jean-Pierre Pignon, Alain Riviere, Isabelle Monnet, Pierre Chomy, Claude Tuchais, Michele Tarayre, Pierre Ruffie
Journal: New England Journal of Medicine (1993)

Moderate increases in the initial doses of certain chemotherapeutic drugs, such as cisplatin and cyclophosphamide, may prolong overall survival in patients with limited small-cell lung cancer.
141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials
Authors: E. Felip, L. Crinò, D.-W. Kim, D.R. Spigel, M. Nishio, T. Mok, G. Scagliotti, D. Cesic, S. Sutradhar, A.T. Shaw
Journal: Journal of Thoracic Oncology (2016)
Immune Activation in Measles
Authors: Diane E. Griffin, Brian J. Ward, Enrique Jauregui, Richard T. Johnson, Abraham Vaisberg
Journal: New England Journal of Medicine (1989)

Measles is associated with alterations in immune regulation that sometimes lead to secondary infections or autoimmune encephalomyelitis. Simultaneously, an effective measles virus–specific immune response develops. To relate immune activation to measles and its complications, we studied the spontaneous proliferation of blood mononuclear cells and circulating levels of soluble interleukin-2 receptor and CD8 T-cell antigens in 126 patients with complicated or uncomplicated measles at various stages of the disease. Spontaneous proliferation of mononuclear cells, which was present through the first week of the rash, was greater in cells from patients with measles (8787±1403 cpm) than in those from healthy children (1529±237 cpm, P<0.0001). Levels of soluble interleukin-2 receptor (3385±195 units per milliliter) and CD8 (4145±437 units per milliliter) were higher in patients with measles than in those with other infectious diseases (2377±440, P = 0.003; 2399±771, P = 0.0374) or in healthy children (865±138, P<0.0001; 1026±169, P<0.0001). Levels of soluble interleukin-2 receptor were elevated before the onset of the rash and remained elevated for several weeks. In contrast, levels of soluble CD8 increased only when the rash appeared, and subsided quickly. Spontaneous proliferation of mononuclear cells and levels of soluble CD8 were similar in patients with uncomplicated disease, pneumonia, or encephalomyelitis, but soluble interleukin-2 receptor levels were lower in patients with encephalomyelitis (2312±314 vs. 3455±247 units per milliliter in uncomplicated measles; P = 0.01). In patients with encephalomyelitis, cerebrospinal fluid levels of soluble CD8 (686±350 units per milliliter), but not interleukin-2 receptor (9±8.3 units per milliliter), were increased. We conclude that the proliferative phase of the immune response, as measured by the release of soluble interleukin-2 receptor, begins before the rash appears, continues for several weeks in those without complications, but does not occur within the nervous system. In contrast, the effector phase of the immune response, as measured by the release of soluble CD8, coincides with the appearance and disappearance of the rash and occurs within the nervous system during encephalomyelitis. (N Engl J Med 1989;320:1667–72.)
<i>PKCδ</i>null mutations in a mouse model of osteoarthritis alter osteoarthritic pain independently of joint pathology by augmenting NGF/TrkA-induced axonal outgrowth
Authors: Ranjan Kc, Xin Li, Jeffrey S Kroin, Zhiqiang Liu, Di Chen, Guozhi Xiao, Brett Levine, Jinyuan Li, John L Hamilton, Andre J van Wijnen, Margaret Piel, Daniel A Shelly, Dovrat Brass, Ela Kolb, Hee-Jeong Im
Journal: Annals of the Rheumatic Diseases (2016)

This article has been retracted.
Local and Systemic Effects of Intradermal Recombinant Interferon-γ in Patients with Lepromatous Leprosy
Authors: Carl F. Nathan, Gilla Kaplan, William R. Levis, Ali Nusrat, Margit D. Witmer, Stephen A. Sherwin, C.K. Job, Carol R. Horowitz, Ralph M. Steinman, Zanvil A. Cohn
Journal: New England Journal of Medicine (1986)

Evidence that interferon-gamma may be a physiologic macrophage-activating factor, and that macrophage activation may be defective in lepromatous leprosy, led us to test the effects of intradermal injection of low doses of recombinant interferon-gamma in six patients with this disease. Interferon-gamma, 1 or 10 micrograms, was administered daily by jet gun for three days into a single cutaneous lesion. A biopsy specimen was taken from the injection site on the sixth study day and compared with specimens obtained previously from a site where no injection had been made or where excipient alone had been injected in the same way as the interferon. Interferon-gamma elicited local effects similar to certain features of delayed-type hypersensitivity reactions or tuberculoid leprosy, including induration, T-cell and monocyte infiltration, keratinocyte proliferation, diminution of epidermal Langerhans cells, and dermal and epidermal cell HLA-DR (Ia) antigen expression. At some of the sites of interferon-gamma injection, there was also an apparent decrease in acid-fast bacilli. Before treatment, monocytes from patients with lepromatous leprosy released 48 percent as much hydrogen peroxide as did monocytes from controls in response to phorbol myristate acetate, and 36 percent as much as those from controls in response to Mycobacterium leprae. When recombinant interferon-gamma was injected, these responses became normal. No toxic effects were observed. These observations suggest that interferon-gamma can mediate certain manifestations of delayed-type hypersensitivity or cell-mediated immunity in vivo, and that recombinant interferon-gamma should be tested for possible therapeutic effects in certain nonviral infectious diseases.
Mycobacterium tuberculosis induces the miR-33 locus to reprogram autophagy and host lipid metabolism
Authors: Mireille Ouimet, Stefan Koster, Erik Sakowski, Bhama Ramkhelawon, Coen van Solingen, Scott Oldebeken, Denuja Karunakaran, Cynthia Portal-Celhay, Frederick J Sheedy, Tathagat Dutta Ray, Katharine Cecchini, Philip D Zamore, Katey J Rayner, Yves L Marcel, Jennifer A Philips, Kathryn J Moore
Journal: Nature Immunology (2016)
Alexander Garden (1728–1793) — Colonial Botanist
Authors: Andrew Kerr
Journal: New England Journal of Medicine (1955)

"BOTANY, required in the eighteenth-century medical curriculum, became a major avocation of many physicians. The first Sherardian Professor of Botany at Oxford was an eighteenth-century physician, and the Regius Professor of Botany at Paris in the early 1700's was a doctor of medicine.1 The two most prominent physicians of the European continent of the eighteenth century — Boerhaave and Haller — made extensive and significant contributions to botany. To the physicians, William Withering, Erasmus Darwin and Jean Baptiste Lamarck, eighteenth-century botany also owed a debt. Carl Linnaeus, physician turned botanist, who named and described over 8000 plants, was the hub . . .
Possible Association between Behçet's Syndrome and Chronic Hepatitis C Virus Infection
Authors: Hans Münke, Fritz Stöckmann, Giuliano Ramadori
Journal: New England Journal of Medicine (1995)

To the Editor: The article by Braveman et al. (Aug.18 issue) 1 does not mention the number of emergency room visits or any admissions in the weeks before the admission for appendicitis.This is important information, because patients with no insurance and those covered by Medicaid have a high number of emergency room visits, as the authors note, and a high number of hospital admissions during which no diagnosis is made.The patients with early signs and symptoms of appendicitis could have had one or more emergency room visits or hospital admissions for undiagnosed appendicitis, only to present later with a frankly perforated appendix.Other abdominal conditions can mimic appendicitis, and emergency ultrasound examination of the appendix has a sensitivity of 80 percent and a specificity of 54 percent for the diagnosis of appendicitis. 2
Case 41-1975
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Bryan T. Woods, James J. Galdabini, Edward P. Richardson
Journal: New England Journal of Medicine (1975)

Presentation of CaseA 49-year-old woman was admitted to the hospital because of seizures.There was a long history of psychologic troubles, with multiple bouts of depression, intermittent abuse of alcohol and frequent complaints of pain in the left anterior portion of the chest accompanied by dyspnea, for which she had been seen repeatedly at the emergency ward of another hospital. One year before admission a clinically benign gastric ulcer was found. Five weeks before entry abdominal pain developed. Several days later the patient vomited bright-red material and was admitted to the other hospital.Physical examination revealed that the blood . . .
Familial Occurrence of Congenital Heart Disease
Authors: Richard A. Carleton, Walter H. Abelmann, Ernest W. Hancock
Journal: New England Journal of Medicine (1958)

THIS is a report of multiple cases of congenital heart disease occurring in three families that have been studied at the Heart Station of the Boston City Hospital. The 9 cases in these families were among a total of 43 persons with congenital heart disease seen between February, 1955, and February, 1958.The three families reported here contain 113 members. We have had the opportunity to examine 43 of these clinically. Electrocardiograms were taken in all those examined, and, when indicated, the evaluation included phonocardiograms, cardiac fluoroscopy and chest roentgenograms. Clinical information was obtained from this or other hospitals concerning . . .
Acute Toxic Reaction to Prolonged Glutethimide Administration
Authors: Israel Zivin, Mervin Shalowitz
Journal: New England Journal of Medicine (1962)

GLUTETHIMIDE is a chemical compound used frequently for the treatment of sleep difficulties as well as for tension and anxiety states. The recommended dosage of this drug is 0.5 to 1.5 gm. either as one dose or in divided doses for treatment of insomnia or anxiety states, and it is characterized as being a nonbarbiturate medication that does not have the side effects commonly noted with the use of barbiturates. A variety of adverse effects have been recorded in the literature after the administration of glutethimide in recommended or excessive dosage, including nausea, skin rash, acute intoxication with overdosage, habituation . . .